Preparation of andrographolide-loaded solid lipid nanoparticles and their in vitro and in vivo evaluations: Characteristics, release, absorption, transports, pharmacokinetics, and antihyperlipidemic activity

Journal of Pharmaceutical Sciences

Volumn 102, Issue 12, 2013, Pages 4414-4425

  Yang, Tao ^a,b   Sheng, Huan Huan ^a   Feng, Nian Ping ^a   Wei, Hai ^a   Wang, Zheng Tao ^a   Wang, Chang Hong ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

absorption; Andrographolide; antihyperlipidemic activity; bioavailability; solid lipid nanoparticles; stability; transport

Indexed keywords

ANDROGRAPHOLIDE; MULTIDRUG RESISTANCE PROTEIN; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERLIPIDEMIC ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; DUODENUM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ABSORPTION; ANDROGRAPHOLIDE; ANTIHYPERLIPIDEMIC ACTIVITY; BIOAVAILABILITY; SOLID LIPID NANOPARTICLES; STABILITY; TRANSPORT;

ANDROGRAPHIS; ANIMALS; CACO-2 CELLS; DITERPENES; DRUG CARRIERS; HUMANS; HYPOLIPIDEMIC AGENTS; INTESTINAL ABSORPTION; LIPIDS; MALE; MICE; NANOPARTICLES; RATS; RATS, WISTAR;

EID: 84888168814     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23758     Document Type: Article

References (33)

1. Abu-Ghefreh AA, Canatan H, Ezeamuzie CI,. 2009. In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharmacol 9 (3): 313-318.
2. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R,. 2003. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol 3 (3): 147-158.
3. Lin TP, Chen SY, Duh PD, Chang LK, Liu YN,. 2008. Inhibition of the Epstein-Barr virus lytic cycle by andrographolide. Biol Pharm Bull 31 (11): 2018-2023.
4. Subramanian R, Asmawi MZ, Sadikun A,. 2008. In vitro alpha-glucosidase and alpha-amylase enzyme inhibitory effects of Andrographis paniculata extract and andrographolide. Acta Biochim Pol 55 (2): 391-398.
5. Trivedi NP, Rawal UM, Patel BP,. 2007. Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integr Cancer Ther 6 (3): 271-280.
6. Yang T, Shi HX, Wang ZT, Wang CH,. 2013. Hypolipidemic effects of andrographolide and neoandrographolide in mice and rats. Phytother Res 27 (4): 618-623.
7. Chen LL, Wang ZH,. 2010. Investigation of basic physical and chemical properties of andrographolide. Pharm Today 20 (1): 41-43.
8. Yu BT, Zhang ZR, Liu WS, Yang TPW,. 2002. Study on stability in vitro of andrographolide. Chin Trad Patent Med 24 (5): 33133.
9. Ye L, Wang T, Tang L, Liu W, Yang Z, Zhou J, Zheng Z, Cai Z, Hu M, Liu Z,. 2011. Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci 100 (11): 5007-5017.
10. He XD, Gong P, Qi CL, He W, Wang LJ, Li WD,. 2011. The anti-tumor effects of andrographolide drop pills on murine B16 melanoma. Acad J Guangdong Coll Pharm 27 (2): 163-165.
11. Wang K, Zhao T, He MZ,. 2009. Preparation of andrographolide solid dispersion systems and their dissolution test in vitro. Chin J Mod Appl Pharm 26 (8): 638-641.
12. Du HN, Iiu X, Qian JF, Ye ML,. 2007. Bioavailability comparison between andrographolide oral microemulsion and andrographolide pill in rabbits. Trad Chin Drug Res Clin Pharmacol 18 (3): 217-219.
13. Ke R, Zhang ZR, Ju JH, Liu Y, Gong T,. 2008. Identification of andrographolide hydroxypropyl-β-cyclodextrin inclusion compound and study on its thermodynamic stability. China Tradit Herb Drugs 39 (4): 518-521.
14. Yu BT, Zhang ZR,. 2009. Preparation and in vitro drug-release behavior of andrographolide liposomes. Chin J Pharm 40 (2): 114-116.
15. Wissing SA, Kayser O, Muller RH,. 2004. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56 (9): 1257-1272.
16. Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV,. 2007. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 335 (1-2): 167-175.
17. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB,. 2006. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 317 (1): 82-89.
18. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H,. 2009. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133 (3): 238-244.
19. Yang T, Sheng HH, Cheng XM, Wang CH, Wang ZT,. 2012. Formula optimization of andrographolide loaded solid lipid nanoparticles by central composite design/response surface methodology. Chin J Pharm 43 (9): 753-755.
20. Wissing SA, Muller RH,. 2002. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J Control Release 81 (3): 225-233.
21. Yang T, Xu C, Wang ZT, Wang CH,. 2013. Comparative pharmacokinetic studies of andrographolide and its metabolite of 14-deoxy-12-hydroxy- andrographolide in rat by ultra-performance liquid chromatography-mass spectrometry. Biomed Chromatogr 27 (7): 931-937.
22. Wu YP, Huo MR, Zhou JP,. 2009. Preparation of silymarin-loaded amphiphilic chitosan micelle and its in situ absorption in rat intestine. Acta Pharm Sin 44 (6): 651-657.
23. Shu-Fang N, Wei-San P, Wei L, Ga-Ni D,. 2005. Study on in situ intestinal absorption of vinpocetine in rats. Chin J Pharm 36 (10): 625-628.
24. 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci 3 (3): E25.
25. Sha XY, Fang ML,. 2004. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Int J Pharm 272 (1-2): 161-171.
26. Kamboj S, Bala S, Nair AB,. 2010. Solid lipid nanoparticles: An effective lipid based technology for poorly water soluble drugs. Int J Pharm Sci Rev Res 5 (2): 78-90.
27. He X, Li J, Gao H, Qiu F, Hu K, Cui X, Yao X,. 2003. Identification of a rare sulfonic acid metabolite of andrographolide in rats. Drug Metab Dispos 31 (8): 983-985.
28. Mahar, Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW,. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303 (3): 1029-1037.
29. Saarinen-Savolainen P, Jarvinen T, Taipale H, Urtti A,. 1997. Method for evaluating drug release from liposomes in sink conditions. Int J Pharm 159 (1): 27-33.
30. Zur, Muhlen A, Schwarz C, Mehnert W,. 1998. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. Eur J Pharm Biopharm 45 (2): 149-155.
31. Liao QF, Yao Y, Wei C, Zhang L, Xie Z,. 2009. Simultaneous determination of andrographolide and dehydroandrographolide in rat plasma by LC/MS/MS and its pharmacokinetics study. World Sci Tech-Mod Tradit Chin Med 11 (6): 847-851.
32. Rubas W, Jezyk N, Grass GM,. 1993. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell-line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 10 (1): 113-118.
33. Zhang HJ, Yao M, Morrison RA, Chong SH,. 2003. Commonly used surfactant, tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26 (9): 768-772.